Introduction
Catailyst expedites drug discovery and development within Biopharma companies by offering cost-effective access to precise scientific and business information via a web-based portal, customizable alerts and modern visualizations.
Catailyst has combined automation and artificial intelligence to understand scientific, clinical and business announcements from various public information sources, such as press releases, SEC filings, trial registrations to create actionable and searchable data points. Catailyst has recently launched a database and data analytics platform to provide access to such data. The company has also developed several real-time alerts and integrated modern visualization.
The Company brings a comprehensive solution for Biotech and Pharma business development teams, clinical development team, investment bankers, investors, and life science consultants to track drug development, monitor competition, follow market trends and inform about recent developments of drug candidates and approved drugs. We use our own extractive AI and NLP methods to generate data instead of repetitive human labor. This sets us apart from competitors who rely on large numbers of employees for data generation.
Problem
Expensive and time consuming to find accurate data within life science industry.
Today, business leaders are constantly asking questions and challenging their decisions to gain competitive advantage in the marketplace. The cost of finding accurate data to support a decision is currently very high and labor intensive due to overwhelming data flow and lack of an integrated data source within the life science industry. Often executives, clinicians, researchers, investors, consultants, bankers are missing critical information.
Today, companies may manage these situations with multiple subscriptions, or a series of internet searches to assemble information. Manual data verification and curation become highly time-consuming, causing delays in business decisions.
To this end, small and medium size companies are most challenged.
Solution
The Solution: Catailyst, Disrupting The Drug Discovery And Development With Data Science: AI, ML, NLP & Predictive Analytics
Catailyst has created a single integrated platform for business, scientific and clinical information and makes it easier for access.
- Our AI technology reads and analyzes different forms of texts published everyday
- We have built strong capabilities of extracting relevant texts from large documents such as SEC filings
- We created validated and established methods of identifying and categorizing relevant data points without human interventions
- In addition, Catailyst has added business process automation to handle large quantity of information flow
- By implementing such a process, the Company processes 500+ press releases, 100+ clinical trials related information, and hundreds of SEC filings everyday
- A patent related to such invention was filed to USPTO in 2020
- PCT applications were filed in certain countries from EU, Canada and India. No patents have been granted.
Today, Catailyst database is utilized for many major decision supports such as strategic priority discussion, deal negotiations, clinical trial designs, business continuity planning and more. Some example data points are below.
- Pipeline by indication
- Conference abstracts
- Competitive intelligence and market landscape
- Future timeline
- Deal Terms
Business Model
The company is currently offering two products. SAAS monthly subscriptions to the database and daily/weekly customizable alerts in a B2B business model.
- Database
- Alerts
- Visualization
Target customers are from three major sectors:
- Executives, business development team & clinicians within Biotech and Pharma
- Consultants and investment bankers
- Investors and business analyst
Market
Catailyst addressable markets intersect Life Science Analytics and Artificial Intelligence in Life Sciences. Both are rapidly growing markets.
Success To Date
- 2019Q4 Partnership with Xelpmoc (Publicly Traded Indian company, listed at Bombay Stock Exchange)
- 2020Q2 AWS Activate award, $25,000 USD grant
- 2020Q2 First Advisor came on board
- 2020Q2 US provisional patent application - Morgan Lewis
- 2020Q3 Multiple Newswire partnerships: Globenewswire; Businesswire; Accesswire; PRNewswire
- 2020-2023 Employed 13 paid short-term employees, employed during Covid-days
- 2020-2023 Non-dilutive Mass Life Science Corporation Intern Challenge Program Funding
- 2021Q2 Major data science technology breakthrough
- 2021Q2 US patent conversion
- 2022Q1 Beta Product Launch
- 2022Q1 First Paid Customer in 2022
- 2022Q4 PCT - International patent applications
Team
Advisors
Use of Proceeds
If the offering's maximum amount of $1,235,000 is raised:
| Use | Value | % of Proceeds |
|---|---|---|
| Salaries - Management | $200,000 | 16.2% |
| Advertising and Marketing | $250,000 | 20.2% |
| Patents | $40,000 | 3.2% |
| Legal and Professional Sevices | $30,000 | 2.4% |
| Research and Development | $108,000 | 8.7% |
| Technology | $228,485 | 18.5% |
| Website | $30,000 | 2.4% |
| Insurance | $8,000 | 0.6% |
| Salaries - Marketing | $100,000 | 8.1% |
| Salaries - Sales | $180,000 | 14.6% |
| Intermediary fees | $60,515 | 4.9% |
Terms
This is an offering of Class A Common Stock, under registration exemption 4(a)(6), in Catailyst Inc. . This offering must raise at least $10,000 by November 16, 2023 at 10:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. Catailyst may issue additional securities to raise up to $1,235,000, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
Financials
These financial statements have been reviewed by an independent Certified Public Accountant.
SEC Filings
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
More Info
Updates
- Nov 17, 2023Primary offering finalized, selling shares
- Nov 8, 2023We've put together a comprehensive recap video...
- Nov 6, 2023Hello Everyone, I want to invite you to join...
- Oct 2, 2023Member Spotlight: Q&A with Catailyst Every...
- Sep 14, 2023Hope your summer went well. Two quick...
- Jun 16, 2023We super excited to inform you that Catailyst...
- Jun 15, 2023Catailyst recently presented a poster at Orphan...
- Jun 14, 2023Hi Everyone, I hope you are able to attend our...
- May 9, 2023In addition to recent partnership with Launchit...
- May 9, 2023Catailyst is presenting a poster at World...
- May 9, 2023Catailyst is looking forward to attend AWS Life...
- May 9, 2023Meet us at Bio-IT next week. Catailyst will be...
- May 3, 2023Catailyst Forms Strategic Partnership with...
- Apr 29, 2023Hi Everyone, Netcapital Demo Day presentation...
- Apr 26, 2023Netcapital is hosting a Virtual Demo Day on...
- Apr 20, 2023Hi Everyone, Thank you all for your continued...
- Apr 12, 2023Catailyst team members are planning to attend...
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. Investors are advised to review our Discussion Board Policy before submitting a comment. For the fastest help with the web site, email help@netcapital.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.